Edgen Stock·Sep 18 2025, 20:25戻る
戻る
Adagene and Exelixis Expand Collaboration for Third Antibody-Drug Conjugate Program
Edgen Stock·Sep 18 2025, 20:25
[1] Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate[2] Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - GlobeNewswire[3] Adagene (ADAG) Expands Collaboration with Exelixis for Antibody-Drug Development - GuruFocus